Update: Daiichi Sankyo says Plexxikon R&D unit will close downJust over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the Share XUpdate: Daiichi Sankyo says Plexxikon R&D unit will close downhttps://pharmaphorum.com/news/daiichi-sankyo-says-plexxikon-rd-unit-will-close-down/
Chasing Roche, Merck unveils adjuvant lung cancer data for KeytrudaMerck & Co’s Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but Share XChasing Roche, Merck unveils adjuvant lung cancer data for Keytrudahttps://pharmaphorum.com/news/chasing-roche-merck-unveils-adjuvant-lung-cancer-data-for-keytruda/
BMS cuts $3.15bn deal with Century for cancer cell therapiesBristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP Share XBMS cuts $3.15bn deal with Century for cancer cell therapieshttps://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/
Amgen grabs EU approval for pathfinder KRAS drug LumykrasAmgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years Share XAmgen grabs EU approval for pathfinder KRAS drug Lumykrashttps://pharmaphorum.com/news/amgen-grabs-eu-approval-for-pathfinder-kras-drug-lumykras/
Roivant joins RNA splicing push with Eisai dealRoivant is the latest pharma group to take a position in the emerging field of therapies targeted at Share XRoivant joins RNA splicing push with Eisai dealhttps://pharmaphorum.com/news/roivant-joins-rna-splicing-push-with-eisai-deal/
FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tagThe FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain Share XFDA gives AbbVie’s c-Met lung cancer ADC a breakthrough taghttps://pharmaphorum.com/news/fda-gives-abbvies-c-met-lung-cancer-adc-a-breakthrough-tag/
J&J goes after another FDA approval for a cancer bispecificJohnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and Share XJ&J goes after another FDA approval for a cancer bispecifichttps://pharmaphorum.com/news/jj-guns-for-another-fda-approval-for-a-cancer-bispecific/
FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tagDaiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) Share XFDA gives Daiichi Sankyo’s HER3 drug a breakthrough taghttps://pharmaphorum.com/news/fda-gives-daiichi-sankyos-her3-lung-cancer-drug-breakthrough-tag/
Sanofi buys US immuno-oncology biotech Amunix for $1 billionSanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US Share XSanofi buys US immuno-oncology biotech Amunix for $1 billionhttps://pharmaphorum.com/news/sanofi-buys-us-immuno-oncology-biotech-amunix-for-1-billion/
Novartis taps immuno-oncology partner BeiGene for TIGIT drugNovartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate Share XNovartis taps immuno-oncology partner BeiGene for TIGIT drughttps://pharmaphorum.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug/
ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphomaGilead Sciences has taken a big step towards positioning its CAR-T therapy Yescarta as an option for previously-untreated Share XASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphomahttps://pharmaphorum.com/news/ash-trial-backs-gileads-yescarta-car-t-in-first-line-lymphoma/
ASH: Gilead, BMS CAR-Ts square off in relapsed lymphomaA pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large Share XASH: Gilead, BMS CAR-Ts square off in relapsed lymphomahttps://pharmaphorum.com/news/ash-gilead-bms-car-ts-square-off-in-relapsed-lymphoma/
ASH: Servier’s Tibsovo poised for first-line used in AMLServier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for Share XASH: Servier’s Tibsovo poised for first-line used in AMLhttps://pharmaphorum.com/news/ash-serviers-tibsovo-poised-for-first-line-used-in-aml/
Roche builds case for TIGIT combo in untreated lung cancerRoche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing Share XRoche builds case for TIGIT combo in untreated lung cancerhttps://pharmaphorum.com/news/roche-builds-case-for-tigit-combo-in-untreated-lung-cancer/
Henlius claims win for PD-1 drug in small cell lung cancerChina’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in Share XHenlius claims win for PD-1 drug in small cell lung cancerhttps://pharmaphorum.com/news/henlius-claims-win-for-pd-1-drug-in-small-cell-lung-cancer/
